SOUFFLÉ
LIVE

Serial Number

97799174

Owner

Soufflé Therapeutics, Inc.

Attorney

Joshua S. Jarvis

Filing Date

Feb 17, 2023

Add to watchlist:

No watchlists yet
View on USPTO

SOUFFLÉ Trademark

Serial Number: 97799174

SOUFFLÉ is a trademark filed by Soufflé Therapeutics, Inc. on February 17, 2023. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

Soufflé Therapeutics, Inc. (3 trademarks)

250 Arsenal Street, Suite 220
Watertown, MA 02472

Entity Type: 03

Trademark Details

Filing Date

February 17, 2023

Registration Date

Not Registered

Published for Opposition

July 9, 2024

Goods & Services

Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastrointestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculoskeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for use in ophthalmology; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthma; vaccines; pharmaceuticals for humans.

Pharmaceutical research and development; consulting services in the field of pharmaceutical research and development; research and development in the pharmaceutical and biotechnology fields; providing information in the field of pharmaceutical research and development; providing medical and scientific research information in the fields of pharmaceuticals and clinical trials

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 3, 2026 EXRA
SOU EXTENSION 3 GRANTED
Mar 3, 2026 EX3G
SOU EXTENSION 3 FILED
Mar 2, 2026 EXT3
SOU TEAS EXTENSION RECEIVED
Mar 2, 2026 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Sep 15, 2025 EXRA
SOU EXTENSION 2 GRANTED
Aug 29, 2025 EX2G
SOU EXTENSION 2 FILED
Aug 29, 2025 EXT2
SOU TEAS EXTENSION RECEIVED
Aug 29, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 12, 2025 EXRA
SOU EXTENSION 1 GRANTED
Feb 11, 2025 EX1G
SOU EXTENSION 1 FILED
Feb 11, 2025 EXT1
SOU TEAS EXTENSION RECEIVED
Feb 11, 2025 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Sep 3, 2024 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jul 9, 2024 NPUB
PUBLISHED FOR OPPOSITION
Jul 9, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jun 19, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 5, 2024 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
May 16, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 16, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 16, 2024 TROA
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Jan 23, 2024 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Jan 23, 2024 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Nov 22, 2023 GNRN
NON-FINAL ACTION E-MAILED
Nov 22, 2023 GNRT
NON-FINAL ACTION WRITTEN
Nov 22, 2023 CNRT
ASSIGNED TO EXAMINER
Nov 16, 2023 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 7, 2023 NWOS
NEW APPLICATION ENTERED
Feb 21, 2023 NWAP